The FDA approves AbbVie's Biologics License Application for etentamig.

Question

Six frontier AI models put this at 73% by 29 Oct 2027. Full reasoning from every model.

WillHappen.ai · Accepted Answer

73% — the median of 6 frontier models, resolving by 2027-10-29.

Answer

Gemini (Google): 78% — Approval hinges on FDA accepting Phase 3 CERVINO efficacy data without a major CRL or timeline-stretching review extension. Standard FDA BLA reviews take 10 to 12 months from submission, fitting tightly inside the October 29, 2027 window. Oncology biologics meeting Phase 3 endpoints clear FDA review roughly 85% of the time, slightly docked here for review-clock slippage. A formal Complete Response Letter or a three-month PDUFA extension triggered by major amendments would push resolution past deadline.

Answer

Claude (Anthropic): 2% — BLA was just submitted; standard FDA review takes 10-12 months, well past this resolution window's start overlap. AbbVie submitted the BLA on October 27, 2026, and standard FDA review timelines run 10-12 months, landing approval decisions around mid-to-late 2027. Even priority review (8 months) would push a decision to roughly June-July 2027, leaving little buffer before the October 29, 2027 deadline for any complication. Any CRL, advisory committee delay, or manufacturing inspection issue would push approval past the resolution date, and such delays are common in oncology/hematology BLAs.

Answer

GPT (OpenAI): 76% — The key variable is whether FDA accepts the CERVINO package without a major efficacy, safety, or CMC deficiency. AbbVie must clear filing review and a likely standard 10-month FDA review, fitting an October 2027 decision date if accepted promptly. Late-stage BLAs from experienced sponsors often win approval, but pivotal-trial, manufacturing, and label disputes still produce delays or CRLs. A filing refusal, priority review, or an early safety signal would move the estimate most; the stated submission date leaves little schedule buffer.

Answer

Grok (xAI): 71% — FDA first-cycle action on the Oct-2026 BLA lands well before the deadline. Filing accepted ~Dec 2026; 6- or 10-month PDUFA date is Apr–Oct 2027, inside the window. Positive P3 oncology BLAs from large sponsors clear first cycle ~70-75% of the time; a CRL typically adds 6+ months and would miss. Unexpected CMC or safety hold is the main thing that would push past 29 Oct 2027.

Answer

DeepSeek (DeepSeek): 62% — Whether FDA clears etentamig hinges on CERVINO data quality and AbbVie's priority-review status, not on any external bottleneck. AbbVie filed the BLA October 27, 2026; a standard 10-month review puts a decision near August 2027, inside the window, while priority review would land earlier. Oncology BLAs from large sponsors with positive Phase 3 data clear at roughly 70-80%, but AbbVie's recent FDA track record includes CRL setbacks that pull this below… The pivotal CERVINO results and any manufacturing or CMC issues are the main failure modes; a complete response letter or a missed user-fee date would flip this to no.

Answer

Qwen (Alibaba): 74% — Standard 12-month PDUFA clock fits the window; main risk is a CRL or manufacturing delay pushing past Oct 2027. Oncology BLAs that reach FDA review are approved ~85-90% of the time, but ~10-15% receive CRLs or miss their PDUFA date. Submission implies positive CERVINO Phase 3 data; multiple myeloma bispecifics (teclistamab, elranatamab) have recent precedent easing regulatory path. A CMC deficiency letter or safety signal would push approval beyond the resolution date — that's the single scenario that flips this to no.

The FDA approves AbbVie's Biologics License Application for etentamig.

A clinical trial begins testing a vascularized, 3D-bioprinted human organ in patients before 2032.

A fully lab-grown solid human organ is successfully transplanted into a patient before 2035.

Standard clinical turnaround for an ex vivo autologous gene editing therapy falls below 14 days before 2030.

An in vivo CRISPR gene editing therapy receives standard FDA approval before 2028.